Status: Recruiting
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)
The aim of this study is to assess the safety and preliminary efficacy of treatment with EXE-346, a live biotherapeutic, which may reduce bowel movement frequency in patients with an ileal pouch-anal anastomosis (IPAA) and lead to a higher quality of life.
Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Exegi Pharma, LLCUpdated: May 28, 2026Locations: 8
Eligibility criteria
Phase 1b Only [+12]
Subject has Crohn's-like disease of the pouch, as indicated by their most recent... [+28]